They offer quick, affordable, and convenient access to medical expertise without the need for in-person visits
Triple-Hormone-Receptor Agonist Retatrutide for Obesity (PubMed PMID 37366315)
The secondary outcomes comprising cardiometabolic risk factors (including high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), body mass index (BMI), insulin sensitivity index adjusted for BMI (ISI), systolic blood pressure (SBP), diastolic blood pressure (DBP)) [33] and multiple-organ complications (liver diseases: metabolic dysfunction-associated steatohepatitis, liver fibrosis, fibrosis in MASLD, liver cirrhosis, hepatocellular carcinoma (HCC), hepatic failure
Several mechanisms may explain why some patients experience tiredness while taking GLP-1 receptor agonists
Someone on insulin needs closer glucose monitoring